Alloimmune Hemolytic Disease of the Fetus and Newborn (RhCc, RhEe, RhD, or Kell Antigen Genotyping)

The Rh blood group is a complex human blood group. Rh antigens are encoded by two genes, RHD and RHCE, and are highly immunogenic. Antibodies against Rh antigens are the major cause of alloimmune hemolytic disease of the newborn (HDFN).¹

The Kell blood group is complex with many antigens encoded by the KEL gene. The two major codominant alleles are KEL*01 and KEL*02 with corresponding K and k antigens. The K antigen is one of the most clinically significant antigens as anti-K causes severe fetal anemia by suppressing fetal red blood cell (RBC) synthesis.² Kell isoimmunization is the third most common cause of HDFN.²

In obstetrics, RBC antigen genotyping is useful when the mother has a clinically significant alloantibody level and the father is phenotypically positive for the corresponding antigen. Paternal genotyping can be used to assess risk for HDFN in offspring by determining copy number for the antigen of interest. Fetal genotyping is useful when the father of the fetus is either heterozygous for the corresponding antigen or unavailable for testing.

DISEASE OVERVIEW

Incidence of HDFN

- 13% of hydrops fetalis is caused by antigen/antibody-mediated RBC hemolysis
- 6–7/1,000 live births with maternal RhD alloimmunization in the U.S.³
- RhD antigen causes ~50% of clinically significant maternal alloimmunization cases⁴
  - Anti-c one of the most common causes of severe HDFN, after anti-D
  - Anti-C, anti-E, and anti-e are less common causes of HDFN
    - When symptoms occur, they are usually mild to moderate⁵
  - ~4% of K negative (k/k) mothers will deliver a K positive baby with potential for HDFN⁶

Symptoms of HDFN

- Fetal hemolytic anemia
- Jaundice
- Hepatosplenomegaly
- Erythroblastosis
- Hydrops fetalis
- Stillbirth

Physiology

- Transplacentally transferred maternal IgG antibodies attack fetal RBCs in response to foreign, paternally inherited antigens in fetus
- >50 different RBC antigens are known to be associated with maternal alloimmunization and HDFN
- Despite routine screening and treatment, anti-D alloimmunization may still occur in some RhD-negative women due to:
  - Blood transfusion
  - Unrecognized miscarriages
  - Failure to receive prophylactic anti-D immunoglobulin during and following pregnancy

Tests to Consider

RhC/c (RHCE) Antigen Genotyping 3002002
Method: Polymerase Chain Reaction/Fluorescence Monitoring

- Genotyping to assess Rh blood group RHCE*2 (C) and RHCE*4 (c)
- Use to determine paternal RhCc genotype when reproductive partner has clinically significant alloantibody
- Determine fetal RhCc genotype when mother has clinically significant alloantibody AND father is either heterozygous or unavailable for testing
- Immucor PreciseType HEA Molecular BeadChip which is FDA-approved for clinical testing

RhD Gene (RHD) Copy Number 0051368
Method: Polymerase Chain Reaction/Fluorescence Monitoring

- Determine paternal RHD gene copy number (heterozygous or homozygous) in phenotypically positive individual when reproductive partner has clinically significant alloantibody
- Determine fetal RHD gene copy number when mother has clinically significant alloantibody AND father is either heterozygous for RHD or unavailable for testing
- This test does not assess for weak or partial RHD genotypes

RhE/e (RHCE) Antigen Genotyping 3002003
Method: Polymerase Chain Reaction/Fluorescence Monitoring

- Genotyping to assess Rh blood group RHCE*3 (E) and RHCE*5 (e)
- Use to determine paternal RhEe genotype when reproductive partner has clinically significant alloantibody
- Determine fetal RhEe genotype when mother has clinically significant alloantibody AND father is either heterozygous or unavailable for testing
- Immucor PreciseType HEA Molecular BeadChip which is FDA-approved for clinical testing
GENETICS

Variants Resulting in RhD Negative Phenotypes

- RhD-negative White individuals
  - Most have complete deletions of both copies of \( RHD \) gene
    - Rarely, a nonfunctional \( RHD \) gene is due to sequence variant, insertions (eg, pseudogene at border of intron 3/exon 4), or a nonfunctional \( RHD-CE-D \) fusion gene
- RhD-negative African Americans
  - 25% have a 37-base-pair insertion inactivating the gene
  - Most others have a nonfunctional fusion gene or complete gene deletion\(^8\)
- RhD-negative Asians
  - 72% have partial or complete gene deletion\(^9\)
  - Remainder have sequence variant(s) or a nonfunctional fusion gene

Inheritance

Codominant

<table>
<thead>
<tr>
<th>Blood Group</th>
<th>Gene</th>
<th>Allele</th>
<th>Antigen (ISBT #)</th>
<th>ISBT Genotype</th>
<th>Variants Tested</th>
<th>Variants Used to Predict Allele</th>
<th>Phenotype Frequency</th>
</tr>
</thead>
</table>
| Rh          | RHCE (NM_020485.5) | C       | RH2             | RHCE*2        | c.307C>T; p.Pro103Ser 109bp insertion | c.307T; p.Ser103 109bp insertion | C: 68%  
                        |       |        |                 |               |                              |                          | AA: 27%  
                        |       |        |                 |               |                              |                          | A: 93%  |
|             |      | c      | RH4             | RHCE*4        | c.307C; p.Pro103 |                              |                          | C: 80%  
                        |       |        |                 |               |                              |                          | AA: 98%  
                        |       |        |                 |               |                              |                          | A: 47%  |
|             | RH3  | E      | RH3             | RHCE*3        | c.676G>C; p.Ala226Pro |                              |                          | C: 29%  
                        |       |        |                 |               |                              |                          | AA: 22%  
                        |       |        |                 |               |                              |                          | A: 39%  |
|             | RH5  | e      | RH5             | RHCE*5        | c.676G; p.Ala226 |                              |                          | C: 98%  
                        |       |        |                 |               |                              |                          | AA: 98%  
                        |       |        |                 |               |                              |                          | A: 96%  |
| RHD (NM_016124.4) | D | RH1    | RH1             | RHDP01        | Presence of the \( RHD \) exons 5, 7, and a 37 base pair insertion in the intron 3/exon 4 boundary. Allelic height ratios are used to determine the number of copies of \( RHD \) as compared to \( RHCE \). | Presence of the \( RHD \) exons 5, 7, and a 37 base pair insertion in the intron 3/exon 4 boundary. Allelic height ratios are used to determine the number of copies of \( RHD \) as compared to \( RHCE \). | C: 15% RhD negative  
                        |       |        |                 |               |                              |                          | AA: 8% RhD negative  
                        |       |        |                 |               |                              |                          | A: <1% RhD negative  |

ISBT, International Society of Blood Transfusion
### TEST INTERPRETATION

**Clinical Sensitivity**
- RhD: 98%\(^8,9,10\)
- RhCc, RhEe, and Kell: 99%

**Analytical Sensitivity/Specificity**
- RhD: 99%
- RhCc, RhEe, and Kell: 99%

**Results**
- **RhCc Genotyping**
  - Homozygosity for C allele is predictive of RhC+c- phenotype
  - Cc compound heterozygosity is predictive of RhC+c+ phenotype
  - Homozygosity for c allele is predictive of RhC-c+ phenotype
- **RhD Copy Number**
  - Presence of one or two copies of *RHD* gene predicts RhD positive phenotype
  - No copies of *RHD* gene predicts RhD negative phenotype
  - Inconclusive results may occur due to:
    - Presence of *RHD* exon 5 but absence of exon 7, or vice versa
    - Presence of the 37-base-pair insertion seen in African Americans
- **RhEe Genotyping**
  - Homozygosity for E allele is predictive of RhE+e- phenotype
  - Ee compound heterozygosity is predictive of RhE+e+ phenotype
  - Homozygosity for e allele is predictive of RhE-e+ phenotype
- **Kell Genotyping**
  - Homozygosity for K allele is predictive of K+k- phenotype
  - Kk compound heterozygosity is predictive of K+k+ phenotype
  - Homozygosity for k allele is predictive of K-k+ phenotype
- Fetuses predicted to be unaffected following prenatal genotyping should continue to be monitored by noninvasive means for the development of erythroblastosis or hydrops

**Limitations**
- Bloody amniotic uid specimens may give false-negative results due to maternal cell contamination
- Rare nucleotide changes leading to altered or partial antigen expression may not be detected
- Genotypes resulting in Rh null phenotypes will not be assessed
- Weak or partial *RHD* genotypes are not assessed
This assay is occasionally limited in predicting genotype due to extreme variation in the Rh locus. False-negative RhC or Rhc predictions may result due to RHCE-D-CE fusion genes.

Diagnostic errors can occur due to rare sequence variations.

Abnormal signal intensities may result in indeterminate genotyping results.

Patients who have had hematopoietic stem cell transplants may have inconclusive results on this test.

References


Related Information

Hemolytic Disease of the Fetus and Newborn